首頁 > 市場調查報告書 > 醫療設備

體外診斷感染疾病

市場調查報告書

商品編碼

1463999

流感診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按測試類型、最終用戶、地區和競爭細分，2019-2029F

Influenza Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End user, By Region and Competition, 2019-2029F

出版日期: 2024年04月15日 | 出版商:

TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年全球流感診斷市場估值為10.8 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為7.05%。，在檢測和管理方面至關重要流感是一種由流感病毒引起的傳染性呼吸道疾病。該市場圍繞著旨在識別和區分流感病毒的診斷工具和技術，為有效的患者護理和公共衛生策略提供至關重要的及時和準確的資訊。該市場受到多種因素的推動，其中最重要的是全球流感病例發生率的增加。季節性流感爆發，加上不可預測的大流行的可能性，凸顯了強力的診斷措施的重要性。由於流感症狀經常與其他呼吸道感染重疊，因此準確的診斷對於適當的治療和遏制策略至關重要。

技術進步在塑造流感診斷市場方面發揮關鍵作用。診斷技術的不斷創新有助於開發更靈敏、更特異的檢測方法。快速分子檢測、基於 PCR 的檢測和即時診斷設備等不斷發展的技術可提高流感檢測的準確性和效率。這些進步不僅有助於早期發現，而且有助於更快速地做出反應，以遏制疫情爆發並防止病毒傳播。對流感的認知和教育的不斷提高進一步推動了市場的成長。醫療保健專業人員和公眾對早期檢測和及時治療重要性的了解不斷增加，導致對診斷服務的需求更高。早期診斷不僅可以改善患者的治療效果，還有助於實施預防措施，限制病毒在社區內的傳播。產生了重大影響市場。這些事件提高了人們對流感病毒的潛在威脅以及需要強大的診斷能力來監測和控制其傳播的認知。從管理這些流行病中獲得的經驗強調了配備先進診斷技術的積極主動、準備充分的醫療保健系統的重要性。政府的措施和支持進一步推動流感診斷市場。世界各地的公共衛生機構都認知到流感監測和控制的重要性。政府投資於流感診斷的研究、開發和部署，通常與醫療機構和私人公司合作，以提高及時、準確檢測的能力。這些舉措有助於市場的整體成長和永續性。流感診斷市場的特點是產品和服務多樣化。診斷測試包括分子測定、快速抗原測試、血清學測試和病毒培養方法。該市場還包括能夠快速進行現場診斷、提供便利和及時結果的即時檢測設備。市場的主要參與者包括診斷公司、製藥公司和研究機構，他們共同努力推動診斷技術和改善流感管理。

主要市場促進因素

意識不斷提高

政府舉措

主要市場挑戰

季節性變化

突變多樣性

診斷特異性

全球流行病

主要市場趨勢

分子診斷的進展

即時檢測

復用技術

人工智慧整合

細分市場洞察

測試類型見解

區域洞察

雅培實驗室有限公司
- 商業概覽
- 公司概況
- 產品服務
- 財務（如果是上市公司）
- 最近的發展
- SWOT分析
貝克頓迪金森公司
科里斯生物概念
迪亞索林有限公司
F.霍夫曼-拉羅氏有限公司
Meridian 生物科學公司
奎德爾公司
積水診斷
賽默飛世爾科技公司

第 15 章：策略建議

第 16 章：關於我們免責聲明

簡介目錄

Product Code: 23249

Global Influenza Diagnostics Market was valued at USD 1.08 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.05% through 2029.The Influenza Diagnostics Market represents a critical facet of global healthcare, pivotal in the detection and management of influenza, a contagious respiratory illness caused by influenza viruses. This market revolves around diagnostic tools and technologies designed to identify and differentiate influenza viruses, providing timely and accurate information crucial for effective patient care and public health strategies. The market is driven by several factors, with the foremost being the increased incidence of influenza cases globally. Seasonal influenza outbreaks, coupled with the potential for unpredictable pandemics, underscore the importance of robust diagnostic measures. As influenza symptoms often overlap with other respiratory infections, the need for accurate diagnostics becomes paramount for appropriate treatment and containment strategies.

Technological advancements play a pivotal role in shaping the Influenza Diagnostics Market. Ongoing innovations in diagnostic technologies contribute to the development of more sensitive and specific assays. Rapid molecular assays, PCR-based tests, and point-of-care diagnostic devices are among the evolving technologies that enhance the accuracy and efficiency of influenza testing. These advancements not only aid in early detection but also facilitate a more rapid response to contain outbreaks and prevent the spread of the virus. Rising awareness and education about influenza further fuel the market's growth. Increased knowledge among healthcare professionals and the general public about the importance of early detection and prompt treatment leads to a higher demand for diagnostic services. Early diagnosis not only improves patient outcomes but also helps in implementing preventive measures to limit the transmission of the virus within communities.Global pandemics, such as the H1N1 influenza pandemic in 2009 and the more recent COVID-19 pandemic, have significantly influenced the Influenza Diagnostics Market. These events have heightened awareness about the potential threats posed by influenza viruses and the need for robust diagnostic capabilities to monitor and control their spread. The experience gained from managing these pandemics has underscored the importance of a proactive and prepared healthcare system equipped with advanced diagnostics. Government initiatives and support further drive the Influenza Diagnostics Market. Public health agencies worldwide recognize the significance of influenza surveillance and control. Governments invest in research, development, and deployment of influenza diagnostics, often collaborating with healthcare institutions and private companies to enhance the capacity for timely and accurate testing. These initiatives contribute to the overall growth and sustainability of the market. The Influenza Diagnostics Market is characterized by a diverse range of products and services. Diagnostic tests include molecular assays, rapid antigen tests, serological tests, and viral culture methods. The market also encompasses point-of-care testing devices that enable rapid on-site diagnosis, offering convenience and timely results. Key players in the market include diagnostic companies, pharmaceutical companies, and research institutions working collaboratively to advance diagnostic technologies and improve influenza management.

Key Market Drivers

Rising Awareness

The Influenza Diagnostics Market is experiencing significant growth propelled by the rising awareness about the importance of timely and accurate influenza diagnostics. Increased knowledge among healthcare professionals, policymakers, and the general public regarding the potential severity and contagious nature of influenza has led to a heightened demand for sophisticated diagnostic tools and technologies. As individuals become more aware of the distinct symptoms of influenza and the need for prompt identification to differentiate it from other respiratory illnesses, there is a growing inclination towards early testing.

Public health campaigns, educational initiatives, and information dissemination through various channels have contributed to this heightened awareness. The emphasis on the significance of early detection not only improves individual patient outcomes but also aids in implementing effective preventive measures at a community level. As a result, there is a greater adoption of advanced diagnostic methods, including molecular assays and point-of-care testing devices, to quickly and accurately identify influenza viruses. This surge in awareness and proactive healthcare-seeking behavior is a driving force behind the expanding Influenza Diagnostics Market, shaping a landscape where the importance of timely and precise influenza testing is recognized and prioritized on a global scale.

Government Initiatives

Government initiatives play a pivotal role in propelling the Influenza Diagnostics Market forward. Recognizing the public health implications of influenza outbreaks, governments worldwide are actively investing in initiatives aimed at enhancing diagnostic capabilities, surveillance, and overall influenza control. These initiatives encompass a spectrum of activities, including research and development funding, collaborative partnerships with healthcare institutions and private companies, and the deployment of comprehensive influenza surveillance programs. Governments allocate substantial resources to support research endeavors focused on advancing diagnostic technologies for influenza. This involves funding for the development of more sensitive and specific diagnostic assays, as well as the creation of innovative point-of-care testing solutions. Collaborative efforts between government agencies and the private sector aim to accelerate the translation of research findings into practical applications, ensuring that cutting-edge diagnostic tools are readily available for healthcare professionals.

In addition, governments actively engage in awareness campaigns to educate healthcare professionals and the general public about the importance of influenza testing and early detection. These campaigns often emphasize the role of diagnostics in effective influenza management, enabling timely treatment and containment strategies. Furthermore, governments implement robust influenza surveillance programs to monitor and track the prevalence of the virus. This involves widespread testing, data collection, and real-time reporting, all of which contribute to a comprehensive understanding of influenza trends. The insights gained from these initiatives aid in formulating evidence-based public health policies and responses to influenza outbreaks.

Key Market Challenges

Seasonal Variability

Seasonal variability poses a significant challenge for the Influenza Diagnostics Market. Influenza exhibits a distinct seasonality, with peak activity during colder months. This variability complicates diagnostic preparedness, as the demand for accurate and timely diagnostics surges seasonally. Healthcare systems must anticipate and adapt to this cyclic demand, ensuring sufficient resources, testing capabilities, and public health infrastructure during peak influenza seasons. The challenge lies in maintaining a delicate balance and optimizing diagnostic capacity without overburdening the healthcare system during non-peak periods. Effective strategies for managing the seasonal ebb and flow of influenza cases are essential for a resilient and responsive diagnostic market.

Mutational Diversity

Mutational diversity in influenza viruses poses a substantial challenge for the Influenza Diagnostics Market. The rapid mutation rate of influenza viruses results in diverse strains, making it challenging to develop universally effective diagnostic assays. The genetic variability requires continuous surveillance and updates to diagnostic tools to ensure the accurate detection of evolving strains. Adaptable diagnostic strategies that can accommodate the mutational diversity of influenza viruses are crucial. The challenge lies in staying ahead of the virus's mutational changes, necessitating ongoing research, collaboration, and innovation to develop diagnostics that can effectively identify and differentiate the diverse influenza strains that emerge over time.

Diagnostic Specificity

Diagnostic specificity poses a notable challenge for the Influenza Diagnostics Market. The symptoms of influenza often overlap with those of other respiratory illnesses, creating difficulties in achieving diagnostic specificity. Distinguishing influenza from similar conditions becomes crucial for timely and appropriate patient management. The challenge lies in developing diagnostic tools that can accurately identify and differentiate influenza viruses, minimizing false positives and negatives. Ongoing research and technological innovations are essential to enhance the specificity of influenza diagnostics, ensuring that healthcare professionals can confidently diagnose influenza and initiate targeted interventions without the risk of misdiagnosis.

Global Pandemics

Global pandemics present a formidable challenge for the Influenza Diagnostics Market. The sudden and widespread nature of influenza outbreaks strains diagnostic capabilities, requiring rapid and scalable responses. The challenge extends beyond routine seasonal preparedness, demanding adaptable diagnostic strategies to address evolving pandemic strains. The unpredictability of pandemic occurrences necessitates a proactive approach in developing diagnostics that can swiftly and accurately identify emerging influenza viruses. The capacity to deploy diagnostics on a global scale during pandemics becomes critical for timely containment and public health responses. Meeting this challenge requires collaborative efforts, innovative technologies, and a robust infrastructure capable of handling the heightened diagnostic demands during pandemics.

Key Market Trends

Advancements in Molecular Diagnostics

Advancements in molecular diagnostics represent a prominent trend in the Influenza Diagnostics Market. The increasing utilization of molecular techniques, such as PCR and nucleic acid amplification, has revolutionized influenza testing, offering enhanced sensitivity and specificity. These advanced molecular diagnostics enable the rapid and accurate detection of influenza viruses, aiding in early diagnosis and effective patient management. Additionally, ongoing research and development in molecular technologies contribute to the continuous improvement of diagnostic assays, ensuring adaptability to emerging influenza strains. The trend towards molecular diagnostics reflects a commitment to precision in influenza testing, fostering a more comprehensive and reliable approach to influenza diagnostics.

Point-of-Care Testing

Point-of-Care Testing (POCT) stands out as a significant trend in the Influenza Diagnostics Market. The increasing adoption of rapid, on-site testing solutions transforms the landscape of influenza diagnostics. POCT devices offer swift results, facilitating immediate clinical decision-making and enabling timely interventions. These tests are particularly valuable in settings where quick and efficient diagnostic outcomes are crucial, such as emergency departments, clinics, and remote locations. The trend towards Point-of-Care Testing reflects a broader healthcare shift towards decentralized diagnostics, emphasizing accessibility and speed, ultimately enhancing the efficiency of influenza diagnosis and contributing to improved patient outcomes.

Multiplexing Technologies

Multiplexing technologies emerge as a key trend in the Influenza Diagnostics Market. The adoption of multiplex assays allows simultaneous detection of multiple respiratory viruses, including various influenza strains. This technology enhances diagnostic efficiency by providing a comprehensive overview of the viral landscape in a single test. Multiplexing not only streamlines the diagnostic process but also aids in distinguishing between different respiratory pathogens, contributing to more accurate and targeted treatment approaches. The trend towards multiplexing technologies aligns with the demand for comprehensive diagnostic solutions, reflecting a paradigm shift towards more integrated and efficient influenza diagnostics in clinical settings.

Integration of AI

The integration of Artificial Intelligence (AI) represents a notable trend in the Influenza Diagnostics Market. AI applications are increasingly employed to enhance the accuracy and efficiency of influenza diagnostics. Machine learning algorithms analyze vast datasets, aiding in the identification of unique patterns associated with influenza viruses. This integration streamlines diagnostic processes, improves predictive capabilities, and supports timely decision-making. AI contributes to a more intelligent and adaptive approach to influenza diagnostics, facilitating the rapid interpretation of complex data and enabling healthcare professionals to stay ahead of emerging viral strains. The trend reflects a broader movement towards leveraging technology for advanced and sophisticated diagnostic solutions.

Segmental Insights

Test Type Insights

Basedon the Test Type, Molecular diagnostic assays dominate the Influenza Diagnostics Market due to their unparalleled precision and sensitivity. These assays, particularly Polymerase Chain Reaction (PCR) tests, offer highly accurate detection of influenza viruses by amplifying and analyzing viral genetic material. Molecular techniques enable early and specific identification of influenza strains, crucial for effective patient management and outbreak control. The dominance of molecular diagnostic assays stems from their ability to provide reliable results, differentiate between influenza subtypes, and contribute to comprehensive surveillance efforts. As technological advancements continue, molecular assays remain at the forefront, defining the gold standard in influenza diagnostics.

Regional Insights

North America dominates the Influenza Diagnostics Market due to robust healthcare infrastructure, high awareness, and proactive influenza management. The region's well-established diagnostic facilities, research initiatives, and a strong emphasis on public health contribute to its dominance. Extensive collaborations between government agencies, private sectors, and academic institutions enhance influenza surveillance and diagnostics. The proactive response to influenza outbreaks, coupled with a high prevalence of diagnostic technologies, positions North America at the forefront. Additionally, a well-informed population and favorable reimbursement policies further drive the adoption of advanced influenza diagnostics, solidifying North America's leading role in shaping the market landscape.

Key Market Players

Abbott Laboratories Limited

Becton, Dickinson and Company

Coris BioConcept

DiaSorin SpA

F. Hoffmann-La Roche Ltd

Meridian Bioscience Inc

Quidel Corporation

Sekisui Diagnostics

Thermo Fisher Scientific Inc

Report Scope:

In this report, the GlobalInfluenza DiagnosticsMarket has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Influenza Diagnostics Market,By Test Type:

Traditional Diagnostic Test
Molecular Diagnostic Assay

Influenza Diagnostics Market,By End-user:

Hospital
Laboratories
Others

Influenza Diagnostics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Influenza Diagnostics Market.

Available Customizations:

Global Influenza Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1.Product Overview

1.1.Market Definition
1.2.Scope of the Market
- 1.2.1.Markets Covered
- 1.2.2.Years Considered for Study
- 1.2.3.Key Market Segmentations

2.Research Methodology

2.1.Objective of the Study
2.2.Baseline Methodology
2.3.Key Industry Partners
2.4.Major Association and Secondary Sources
2.5.Forecasting Methodology
2.6.Data Triangulation Validation
2.7.Assumptions and Limitations

3.Executive Summary

3.1.Overview of the Market
3.2.Overview of Key Market Segmentations
3.3.Overview of Key Market Players
3.4.Overview of Key Regions/Countries
3.5.Overview of Market Drivers, Challenges, Trends

4.Global Influenza Diagnostics Market Outlook

4.1.Market Size Forecast
- 4.1.1.By Value
4.2.Market Share Forecast
- 4.2.1.By Test Type (Traditional Diagnostic Test, Molecular Diagnostic Assay)
- 4.2.2.By End user (Hospital, Laboratories, Others)
- 4.2.3.By Region
- 4.2.4.By Company (2023)
4.3.Market Map
- 4.3.1.By Test Type
- 4.3.2.By End-user
- 4.3.3.By Region

5.Asia Pacific Influenza Diagnostics Market Outlook

5.1.Market Size Forecast
- 5.1.1.By Value
5.2.Market Share Forecast
- 5.2.1.By Test Type
- 5.2.2.By End user
- 5.2.3.By Country
5.3.Asia Pacific: Country Analysis
- 5.3.1.China Influenza Diagnostics Market Outlook
  - 5.3.1.1.Market Size Forecast
    - 5.3.1.1.1.By Value
  - 5.3.1.2.Market Share Forecast
    - 5.3.1.2.1.By Test Type
    - 5.3.1.2.2.By End user
- 5.3.2.India Influenza Diagnostics Market Outlook
  - 5.3.2.1.Market Size Forecast
    - 5.3.2.1.1.By Value
  - 5.3.2.2.Market Share Forecast
    - 5.3.2.2.1.By Test Type
    - 5.3.2.2.2.By End user
- 5.3.3.Australia Influenza Diagnostics Market Outlook
  - 5.3.3.1.Market Size Forecast
    - 5.3.3.1.1.By Value
  - 5.3.3.2.Market Share Forecast
    - 5.3.3.2.1.By Test Type
    - 5.3.3.2.2.By End user
- 5.3.4.Japan Influenza Diagnostics Market Outlook
  - 5.3.4.1.Market Size Forecast
    - 5.3.4.1.1.By Value
  - 5.3.4.2.Market Share Forecast
    - 5.3.4.2.1.By Test Type
    - 5.3.4.2.2.By End user
- 5.3.5.South Korea Influenza Diagnostics Market Outlook
  - 5.3.5.1.Market Size Forecast
    - 5.3.5.1.1.By Value
  - 5.3.5.2.Market Share Forecast
    - 5.3.5.2.1.By Test Type
    - 5.3.5.2.2.By End user

6.Europe Influenza Diagnostics Market Outlook

6.1.Market Size Forecast
- 6.1.1.By Value
6.2.Market Share Forecast
- 6.2.1.By Test Type
- 6.2.2.By End user
- 6.2.3.By Country
6.3.Europe: Country Analysis
- 6.3.1.France Influenza Diagnostics Market Outlook
  - 6.3.1.1.Market Size Forecast
    - 6.3.1.1.1.By Value
  - 6.3.1.2.Market Share Forecast
    - 6.3.1.2.1.By Test Type
    - 6.3.1.2.2.By End user
- 6.3.2.Germany Influenza Diagnostics Market Outlook
  - 6.3.2.1.Market Size Forecast
    - 6.3.2.1.1.By Value
  - 6.3.2.2.Market Share Forecast
    - 6.3.2.2.1.By Test Type
    - 6.3.2.2.2.By End user
- 6.3.3.Spain Influenza Diagnostics Market Outlook
  - 6.3.3.1.Market Size Forecast
    - 6.3.3.1.1.By Value
  - 6.3.3.2.Market Share Forecast
    - 6.3.3.2.1.By Test Type
    - 6.3.3.2.2.By End user
- 6.3.4.Italy Influenza Diagnostics Market Outlook
  - 6.3.4.1.Market Size Forecast
    - 6.3.4.1.1.By Value
  - 6.3.4.2.Market Share Forecast
    - 6.3.4.2.1.By Test Type
    - 6.3.4.2.2.By End user
- 6.3.5.United Kingdom Influenza Diagnostics Market Outlook
  - 6.3.5.1.Market Size Forecast
    - 6.3.5.1.1.By Value
  - 6.3.5.2.Market Share Forecast
    - 6.3.5.2.1.By Test Type
    - 6.3.5.2.2.By End user

7.North America Influenza Diagnostics Market Outlook

7.1.Market Size Forecast
- 7.1.1.By Value
7.2.Market Share Forecast
- 7.2.1.By Test Type
- 7.2.2.By End user
- 7.2.3.By Country
7.3.North America: Country Analysis
- 7.3.1.United States Influenza Diagnostics Market Outlook
  - 7.3.1.1.Market Size Forecast
    - 7.3.1.1.1.By Value
  - 7.3.1.2.Market Share Forecast
    - 7.3.1.2.1.By Test Type
    - 7.3.1.2.2.By End user
- 7.3.2.Mexico Influenza Diagnostics Market Outlook
  - 7.3.2.1.Market Size Forecast
    - 7.3.2.1.1.By Value
  - 7.3.2.2.Market Share Forecast
    - 7.3.2.2.1.By Test Type
    - 7.3.2.2.2.By End user
- 7.3.3.Canada Influenza Diagnostics Market Outlook
  - 7.3.3.1.Market Size Forecast
    - 7.3.3.1.1.By Value
  - 7.3.3.2.Market Share Forecast
    - 7.3.3.2.1.By Test Type
    - 7.3.3.2.2.By End user

8.South America Influenza Diagnostics Market Outlook

8.1.Market Size Forecast
- 8.1.1.By Value
8.2.Market Share Forecast
- 8.2.1.By Test Type
- 8.2.2.By End user
- 8.2.3.By Country
8.3.South America: Country Analysis
- 8.3.1.Brazil Influenza Diagnostics Market Outlook
  - 8.3.1.1.Market Size Forecast
    - 8.3.1.1.1.By Value
  - 8.3.1.2.Market Share Forecast
    - 8.3.1.2.1.By Test Type
    - 8.3.1.2.2.By End user
- 8.3.2.Argentina Influenza Diagnostics Market Outlook
  - 8.3.2.1.Market Size Forecast
    - 8.3.2.1.1.By Value
  - 8.3.2.2.Market Share Forecast
    - 8.3.2.2.1.By Test Type
    - 8.3.2.2.2.By End user
- 8.3.3.Colombia Influenza Diagnostics Market Outlook
  - 8.3.3.1.Market Size Forecast
    - 8.3.3.1.1.By Value
  - 8.3.3.2.Market Share Forecast
    - 8.3.3.2.1.By Test Type
    - 8.3.3.2.2.By End user

9.Middle East and Africa Influenza Diagnostics Market Outlook

9.1.Market Size Forecast
- 9.1.1.By Value
9.2.Market Share Forecast
- 9.2.1.By Test Type
- 9.2.2.By End user
- 9.2.3.By Country
9.3.MEA: Country Analysis
- 9.3.1.South Africa Influenza Diagnostics Market Outlook
  - 9.3.1.1.Market Size Forecast
    - 9.3.1.1.1.By Value
  - 9.3.1.2.Market Share Forecast
    - 9.3.1.2.1.By Test Type
    - 9.3.1.2.2.By End user
- 9.3.2.Saudi Arabia Influenza Diagnostics Market Outlook
  - 9.3.2.1.Market Size Forecast
    - 9.3.2.1.1.By Value
  - 9.3.2.2.Market Share Forecast
    - 9.3.2.2.1.By Test Type
    - 9.3.2.2.2.By End user
- 9.3.3.UAE Influenza Diagnostics Market Outlook
  - 9.3.3.1.Market Size Forecast
    - 9.3.3.1.1.By Value
  - 9.3.3.2.Market Share Forecast
    - 9.3.3.2.1.By Test Type
    - 9.3.3.2.2.By End user

10.Market Dynamics

10.1.Drivers
10.2.Challenges

11.Market Trends Developments

11.1.Recent Developments
11.2.Product Launches
11.3.Mergers Acquisitions

12.Global Influenza Diagnostics Market: SWOT Analysis

13.Porter's Five Forces Analysis

13.1.Competition in the Industry
13.2.Potential of New Entrants
13.3.Power of Suppliers
13.4.Power of Customers
13.5.Threat of Substitute Product

14.Company Profile

14.1.Abbott Laboratories Limited
- 14.1.1.Business Overview
- 14.1.2.Company Snapshot
- 14.1.3.Product Services
- 14.1.5.Financials (In case of listed)
- 14.1.6.Recent Developments
- 14.1.7.SWOT Analysis
14.2.Becton, Dickinson and Company
14.3.Coris BioConcept
14.4.DiaSorin SpA
14.5.F. Hoffmann-La Roche Ltd
14.6.Meridian Bioscience Inc
14.7.Quidel Corporation
14.8.Sekisui Diagnostics
14.9.Thermo Fisher Scientific Inc